MA39493A - Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl) ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase, et compositions pharmaceutiques contenant celle-ci - Google Patents

Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl) ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase, et compositions pharmaceutiques contenant celle-ci

Info

Publication number: MA39493A
Authority: MA; Morocco
Prior art keywords: oxazino; benzotriazine; dione; fluorophenyl; cyclopropyl
Prior art date: 2014-04-07

Application number

MA039493A

Other languages

English (en)

Inventor

Sylvie Bretin

Maria Pueyo

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-07

Filing date

2015-04-03

Publication date

2015-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51383800&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39493(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-04-03 Application filed by Servier Lab filed Critical Servier Lab

2015-10-15 Publication of MA39493A publication Critical patent/MA39493A/fr

Links

JHCFQXNWYDLBOG-UHFFFAOYSA-N 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione Chemical compound FC1=CC=CC(CCN2C(C3=CC=4OCN(C(=O)C=4C=C3N=N2)C2CC2)=O)=C1 JHCFQXNWYDLBOG-UHFFFAOYSA-N 0.000 title 1
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 title 1
239000000544 cholinesterase inhibitor Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Emergency Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MA039493A 2014-04-07 2015-04-03 Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl) ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase, et compositions pharmaceutiques contenant celle-ci MA39493A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR1453046A FR3019464B1 (fr)	2014-04-07	2014-04-07	Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number	Publication Date
MA39493A true MA39493A (fr)	2015-10-15

Family

ID=51383800

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA039493A MA39493A (fr)	2014-04-07	2015-04-03	Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl) ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase, et compositions pharmaceutiques contenant celle-ci

Country Status (19)

Country	Link
US (1)	US20170027949A1 (fr)
EP (1)	EP3129059A1 (fr)
JP (1)	JP2017510597A (fr)
KR (1)	KR20160134854A (fr)
CN (1)	CN106163563A (fr)
AU (1)	AU2015245416A1 (fr)
CA (1)	CA2944750A1 (fr)
CL (1)	CL2016002518A1 (fr)
EA (1)	EA201692006A1 (fr)
FR (1)	FR3019464B1 (fr)
MA (1)	MA39493A (fr)
MD (1)	MD20160115A2 (fr)
MX (1)	MX2016013118A (fr)
PE (1)	PE20170332A1 (fr)
PH (1)	PH12016501982A1 (fr)
RU (1)	RU2016143382A (fr)
SG (1)	SG11201608152RA (fr)
WO (1)	WO2015155451A1 (fr)
ZA (1)	ZA201606873B (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2007519733A (ja) *	2004-01-26	2007-07-19	コーテックスファーマシューティカルズインコーポレーティッド	アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法
AP2502A (en) *	2007-01-03	2012-10-23	Servier Lab	3-substituted-[1,2,3]-benzotriazinone compound forenhancing glutamatergic synaptic responses
EP2195303A4 (fr) *	2007-09-20	2011-07-20	Cortex Pharma Inc	1,2,3-triazine-4-ones 3-substituées et 1,3-pyrimidinones 3-substituées pour améliorer les réponses synaptiques glutamatergiques

2014
- 2014-04-07 FR FR1453046A patent/FR3019464B1/fr active Active
2015
- 2015-04-03 MX MX2016013118A patent/MX2016013118A/es unknown
- 2015-04-03 RU RU2016143382A patent/RU2016143382A/ru not_active Application Discontinuation
- 2015-04-03 US US15/302,245 patent/US20170027949A1/en not_active Abandoned
- 2015-04-03 AU AU2015245416A patent/AU2015245416A1/en not_active Abandoned
- 2015-04-03 MD MDA20160115A patent/MD20160115A2/ro not_active Application Discontinuation
- 2015-04-03 EP EP15719502.5A patent/EP3129059A1/fr not_active Withdrawn
- 2015-04-03 MA MA039493A patent/MA39493A/fr unknown
- 2015-04-03 JP JP2016561308A patent/JP2017510597A/ja active Pending
- 2015-04-03 KR KR1020167030840A patent/KR20160134854A/ko not_active Withdrawn
- 2015-04-03 PE PE2016001884A patent/PE20170332A1/es not_active Application Discontinuation
- 2015-04-03 CN CN201580018480.7A patent/CN106163563A/zh not_active Withdrawn
- 2015-04-03 EA EA201692006A patent/EA201692006A1/ru unknown
- 2015-04-03 WO PCT/FR2015/050879 patent/WO2015155451A1/fr not_active Ceased
- 2015-04-03 CA CA2944750A patent/CA2944750A1/fr not_active Abandoned
- 2015-04-03 SG SG11201608152RA patent/SG11201608152RA/en unknown
2016
- 2016-10-04 CL CL2016002518A patent/CL2016002518A1/es unknown
- 2016-10-05 PH PH12016501982A patent/PH12016501982A1/en unknown
- 2016-10-06 ZA ZA2016/06873A patent/ZA201606873B/en unknown

Also Published As

Publication number	Publication date
RU2016143382A (ru)	2018-05-07
CL2016002518A1 (es)	2017-03-17
ZA201606873B (en)	2018-11-28
WO2015155451A1 (fr)	2015-10-15
EP3129059A1 (fr)	2017-02-15
FR3019464B1 (fr)	2016-05-06
PE20170332A1 (es)	2017-04-15
SG11201608152RA (en)	2016-11-29
KR20160134854A (ko)	2016-11-23
FR3019464A1 (fr)	2015-10-09
EA201692006A1 (ru)	2017-02-28
CA2944750A1 (fr)	2015-10-15
MX2016013118A (es)	2017-01-20
AU2015245416A1 (en)	2016-10-27
MD20160115A2 (ro)	2017-02-28
JP2017510597A (ja)	2017-04-13
CN106163563A (zh)	2016-11-23
PH12016501982A1 (en)	2017-01-09
US20170027949A1 (en)	2017-02-02

Publication	Publication Date	Title
CA2956871C (fr)	2021-05-18	Composes actifs envers des bromodomaines
IL254714A0 (en)	2017-11-30	History of quinoline and pharmaceutical preparations containing them
WO2016011390A8 (fr)	2016-04-07	Agents d'inhibition de l'irak 4
IL250890B (en)	2019-12-31	Compounds for the inhibition of indoleamine-2-3-dioxygenase and pharmaceutical preparations containing them
MX2016016593A (es)	2017-04-27	Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
EP3140291A4 (fr)	2018-01-10	Sulfonamide de tétrahydroquinoline et composés apparentés destinés à servir d'agonistes de rory et pour le traitement de maladies
EP3135667A4 (fr)	2017-11-01	Nouveaux dérivés de 2-amino-pyridine et 2-amino-pyrimidine et leur utilisation médicinale
PT3421038T (pt)	2020-04-22	Compostos de naftiridina, combinações médicas e sua utilização
PH12017500348B1 (en)	2017-07-17	Tetrahydroquinoline derivatives as bromodomain inhibitors
IL252897A0 (en)	2017-08-31	Indanyl compounds, pharmaceutical preparations and their medical uses
IL248773B (en)	2019-12-31	History -6,1-Naphthyridine-5,4-Dione and pharmaceutical preparations containing them
GB2590189B (en)	2022-10-19	Lycorine derivative, and pharmaceutical composition and use thereof
MX382092B (es)	2025-03-04	Compuestos heterocíclicos para el tratamiento de enfermedades.
EP3291818A4 (fr)	2018-12-12	Compositions et procédés pour l'administration d'agents thérapeutiques dans le côlon
EP3443951B8 (fr)	2022-11-02	Agent surgraissant et composition de soin personnel
PH12016502480A1 (en)	2017-04-10	Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
EP3199163A4 (fr)	2018-06-20	Composition de doxycycline dans des liposomes pour la prévention, l'amélioration et/ou le traitement de pathologies oculaires
MA39493A (fr)	2015-10-15	Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl) ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase, et compositions pharmaceutiques contenant celle-ci
WO2015181837A3 (fr)	2016-02-18	Nouveaux composés utilisés comme agents anti-tuberculeux
ZA201607353B (en)	2018-05-30	Bicyclic derivatives and pharmaceutical composition including the same
WO2016073652A8 (fr)	2017-05-04	Iminosucres utiles pour le traitement de maladies virales
WO2016083315A8 (fr)	2017-05-04	Utilisation d'antagonistes d'ox1r pour le traitement de maladies intestinales inflammatoires
HK1233958A1 (en)	2018-02-09	Novel combination between 8-cyclopropyl-3-[2-(3-fluorophenyl) ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione and an acetylcholinesterase inhibitor, and pharmaceutical compositions containing same
FR3034019B1 (fr)	2017-03-17	Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
EP3094330A4 (fr)	2017-09-27	Traitement de la maladie de crohn au moyen de faibles doses de laquinimod